Joincare(SH:600380)2015-04-29 16:00Financial Performance - Total revenue for Q1 2015 reached CNY 2,116,591,711.88, an increase of 22.15% compared to CNY 1,732,745,963.48 in the same period last year[9] - Net profit attributable to shareholders was CNY 178,273,480.71, representing a 48.32% increase from CNY 120,196,075.15 year-on-year[9] - Basic earnings per share rose to CNY 0.1153, a 48.20% increase from CNY 0.0778 in the same period last year[9] - Net profit for Q1 2015 was ¥289,373,768.42, representing a 41.3% increase from ¥204,901,449.56 in Q1 2014[38] - The net profit attributable to shareholders of the parent company was ¥178,273,480.71, compared to ¥120,196,075.15 in the previous year, marking a 48.3% growth[38] Cash Flow - The net cash flow from operating activities for the period was CNY 179,481,337.52, a decrease of 6.18% compared to CNY 191,305,731.53 in the previous year[9] - Cash flow from operating activities decreased by 6.18% to ¥179.48 million due to increased material payments and R&D expenses[16] - Cash flow from investing activities improved by 32.10% to -¥137.04 million due to reduced capital expenditures by subsidiaries[16] - Cash flow from financing activities decreased by 61.15% to ¥122.67 million mainly due to loan repayments by subsidiaries[16] - Cash flow from operating activities generated ¥179,481,337.52, a decrease of 6.4% from ¥191,305,731.53 in the previous year[43] Assets and Liabilities - The total assets at the end of the reporting period were CNY 12,619,769,925.09, up 4.43% from CNY 12,084,314,377.97 at the end of the previous year[9] - The total current assets increased to ¥5,660,622,656.21 from ¥5,144,474,444.98, representing an increase of approximately 10%[30] - Total liabilities increased slightly to ¥5,568,698,498.60 from ¥5,542,798,683.94, showing a marginal rise of about 0.5%[31] - Total assets as of March 31, 2015, amounted to ¥4,723,728,997.85, an increase from ¥4,674,359,115.63 at the beginning of the year[35] - Total liabilities as of March 31, 2015, were ¥2,230,023,533.06, compared to ¥2,176,766,733.71 at the start of the year[35] Shareholder Information - The number of shareholders as of the end of the reporting period was 62,131[11] - The largest shareholder, Shenzhen Baiye Yuan Investment Co., Ltd., held 48.03% of the shares, with 612,620,000 shares pledged[11] Government Subsidies and Other Income - The company received government subsidies amounting to CNY 65,221,179.81 during the period[9] - Non-operating income increased by 186.46% to ¥65.56 million primarily from government subsidies received by subsidiaries[16] Expenses - Total operating costs for Q1 2015 were ¥1,842,429,428.25, up 21.3% from ¥1,518,600,453.36 in Q1 2014[38] - Management expenses increased by 31.59% to ¥185.32 million mainly due to R&D investments from subsidiaries[16] - The company incurred financial expenses of ¥25,604,552.87, which is a significant increase from ¥17,748,067.73 in Q1 2014[41] Commitments and Governance - The company has committed to not engage in any direct or indirect competition with Lizhu Group in terms of drug research, development, production, and sales[21] - The company has established a commitment to ensure that any new business opportunities are first offered to Lizhu Group under reasonable and fair terms[21] - The company has committed to ensuring compliance with the commitments made to its independent directors, enhancing governance and oversight[24]